{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+B%3A+Treatment+D", "query": { "intervention": "Part B: Treatment D" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 283, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+B%3A+Treatment+D&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-21T19:21:55.591Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00903617", "title": "Study to Test GSK256073 in Patients With Dyslipidemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dyslipidaemias", "Dyslipidemias" ], "interventions": [ { "name": "GSK256073", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Niaspan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 80, "start_date": "2009-06-15", "completion_date": "2010-02-16", "has_results": true, "last_update_posted_date": "2019-12-05", "last_synced_at": "2026-09-21T19:21:55.591Z", "location_count": 11, "location_summary": "Pembroke Pines, Florida • Indianapolis, Indiana • Louisville, Kentucky + 8 more", "locations": [ { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Auburn", "state": "Maine" }, { "city": "Brooklyn Center", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00903617" }, { "nct_id": "NCT06293742", "title": "ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "ECC5004", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eccogene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2024-02-08", "completion_date": "2024-04-15", "has_results": false, "last_update_posted_date": "2024-07-22", "last_synced_at": "2026-09-21T19:21:55.591Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06293742" }, { "nct_id": "NCT05716854", "title": "Electrophysiological Effects of Potential QT Prolonging Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug-induced QT Prolongation", "Pharmacokinetics", "Pharmacodynamics" ], "interventions": [ { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Pimozide", "type": "DRUG" }, { "name": "Placebo (Part 1)", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Cobicistat", "type": "DRUG" }, { "name": "Moxifloxacin and Cobicistat", "type": "DRUG" }, { "name": "Placebo (Part 2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Food and Drug Administration (FDA)", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 44, "start_date": "2023-03-21", "completion_date": "2023-06-13", "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-09-21T19:21:55.591Z", "location_count": 1, "location_summary": "West Bend, Wisconsin", "locations": [ { "city": "West Bend", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05716854" }, { "nct_id": "NCT02850406", "title": "Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Voxelotor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Months to 17 Years" }, "enrollment_count": 147, "start_date": "2016-07-05", "completion_date": "2023-10-02", "has_results": true, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-09-21T19:21:55.591Z", "location_count": 13, "location_summary": "Brentwood, California • Washington D.C., District of Columbia • Atlanta, Georgia + 9 more", "locations": [ { "city": "Brentwood", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02850406" }, { "nct_id": "NCT00352443", "title": "S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "lapatinib ditosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2006-09", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-09-21T19:21:55.591Z", "location_count": 6, "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00352443" }, { "nct_id": "NCT04032834", "title": "A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece", "type": "COMBINATION_PRODUCT" }, { "name": "VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask", "type": "COMBINATION_PRODUCT" }, { "name": "1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece", "type": "COMBINATION_PRODUCT" }, { "name": "1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask", "type": "COMBINATION_PRODUCT" }, { "name": "0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece", "type": "COMBINATION_PRODUCT" }, { "name": "0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Vectura Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 34, "start_date": "2017-02-20", "completion_date": "2017-05-22", "has_results": false, "last_update_posted_date": "2019-07-25", "last_synced_at": "2026-09-21T19:21:55.591Z", "location_count": 2, "location_summary": "Tempe, Arizona • Anaheim, California", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04032834" }, { "nct_id": "NCT04634552", "title": "A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematological Malignancies" ], "interventions": [ { "name": "Talquetamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 510, "start_date": "2021-02-01", "completion_date": "2029-03-30", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-21T19:21:55.591Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634552" }, { "nct_id": "NCT05228249", "title": "Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Loncastuximab Tesirine", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-04", "completion_date": "2027-10-01", "has_results": false, "last_update_posted_date": "2023-01-13", "last_synced_at": "2026-09-21T19:21:55.591Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05228249" }, { "nct_id": "NCT03438461", "title": "A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Seltorexant 40 mg", "type": "DRUG" }, { "name": "Seltorexant 20 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 49, "start_date": "2018-02-09", "completion_date": "2018-05-30", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-09-21T19:21:55.591Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03438461" }, { "nct_id": "NCT05797701", "title": "A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Amyotrophic Lateral Sclerosis (Healthy Volunteers)" ], "interventions": [ { "name": "SAR443820", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 18, "start_date": "2021-07-28", "completion_date": "2021-09-06", "has_results": false, "last_update_posted_date": "2023-04-04", "last_synced_at": "2026-09-21T19:21:55.591Z", "location_count": 1, "location_summary": "Saint Paul, Minnesota", "locations": [ { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05797701" } ] }